Product Details
MOUNJARO® Prefilled Pen (Tirzepatide)* Inj 12.5mg/.5ml
Manufacturer: Eli Lily and Company
MFG#: 00002-1460-80
PID: 639213
1/EA
$ *.**
In StockAdditional Information
| Product Name | MOUNJARO® (tirzepatide) injection |
| Dosage Form | Prefilled pen, subcutaneous injection |
| Strength | 12.5 mg/0.5 mL |
| Active Ingredient | Tirzepatide |
| NDC Number | 00002-1460-80 |
| Indication | Improves glycemic control in adults with type 2 diabetes mellitus |
| Administration | Once weekly, subcutaneously in abdomen, thigh, or upper arm |
| Storage Conditions | Refrigerate (36°F–46°F); may be stored at room temp (up to 86°F) for 21 days |
| Contraindications | Personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) |
| Warnings & Precautions | Risk of thyroid C-cell tumors, pancreatitis, hypoglycemia, acute kidney injury, hypersensitivity reactions, and diabetic retinopathy complications |
| Adverse Reactions | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite |
| Manufacturer | Eli Lilly and Company |
Description
MOUNJARO® (tirzepatide) is a once-weekly injectable prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. The prefilled pen delivers a precise 12.5 mg/0.5 mL dose, offering convenience and ease of use for patients. MOUNJARO® should be stored refrigerated, but can be kept at room temperature for up to 21 days if needed.
Patients using MOUNJARO® should be monitored for potential side effects, including gastrointestinal symptoms (e.g., nausea, diarrhea) and more serious risks such as pancreatitis or thyroid tumors. It is contraindicated in individuals with a history of medullary thyroid carcinoma or MEN 2. Healthcare providers should review the full prescribing information and counsel patients on proper administration, storage, and signs of adverse reactions.
MOUNJARO® represents an innovative therapeutic option for managing type 2 diabetes, with clinical trials demonstrating significant improvements in glycemic control and potential weight loss benefits.
For complete prescribing information, refer to the DailyMed link or consult the official FDA-approved label.
This summary is for informational purposes only and does not replace professional medical advice. Always consult a healthcare provider before starting or changing treatment.
Frequently Asked Questions (FAQs)
The cost of MOUNJARO® Prefilled Pen (Tirzepatide)* Inj 12.5mg/.5ml is $$0.00
MOUNJARO® Prefilled Pen (Tirzepatide)* Inj 12.5mg/.5ml is manufactured by Eli Lily and Company.
You can purchase MOUNJARO® Prefilled Pen (Tirzepatide)* Inj 12.5mg/.5ml on our website at https://preview_supplies.pipelinemedical.com/product/detail/mounjaro-prefilled-pen-tirzepatide-inj-12-5mg-5ml-639213